Peptilex – The Peptide Encyclopedia
- 34 peptides – from semaglutide to BPC-157 – in one book
- An evidence grade (A–E) and the key studies for every peptide
- Where each one stands in 2026 – US, EU and Switzerland
Hormones & growth
Tesamorelin
- Type
- Synthetic analogue of growth hormone–releasing hormone (GHRH)
- Main use or focus
- Reduction of excess abdominal fat in people with HIV and lipodystrophy
- Also known as
- Egrifta
Key studies from the book
412 people with HIV and abdominal fat gain, 26 weeks; visceral fat down 15.2 percent versus up 5.0 percent on placebo.
Falutz J et al. – New England Journal of Medicine, 2007404 people, 26 weeks; visceral fat down 10.9 percent versus 0.6 percent, about 18 percent after 12 months.
Falutz J et al. – Journal of Acquired Immune Deficiency Syndromes, 201061 people with HIV and fatty liver, 12 months; liver fat down 37 percent relative to baseline; normal liver fat in 35 versus 4 percent.
Stanley TL et al. – The Lancet HIV, 2019
All key studies, risks and open questions are in the book.
Research at a glance
All papers95
Human studies76
Animal studies only1
Randomized trials21
Meta-analyses & systematic reviews3
Source: PubMed and ClinicalTrials.gov via the Peptilex study database
ongoing / startingcompleted / other
Phase 24
Phase 41
Other2
Source: PubMed and ClinicalTrials.gov via the Peptilex study database
1
2016
1
12018
2020
2022
2024
1
2026
Source: PubMed and ClinicalTrials.gov via the Peptilex study database
Go deeper
Full profile in the book
What it is, how it acts, the key studies, risks and open questions.
Registered trials
ClinicalTrials.gov · name in study title · ongoing first
| Study | Phase | Status | Participants | Start |
|---|---|---|---|---|
| Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV NCT06554717Massachusetts General Hospital | Phase 2 | Recruiting | 100 | Jul 2025 |
| Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury NCT03150511Johns Hopkins University | Phase 2 | Recruiting | 36 | Jun 2018 |
| Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons NCT02572323University of California, San Diego | Phase 2 | Completed | 73 | Feb 2017 |
| Tesamorelin Effects on Liver Fat and Histology in HIV NCT02196831Massachusetts General Hospital | – | Completed | 61 | Jul 2015 |
| Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® NCT01591902Theratechnologies | Phase 4 | Stopped early | 129 | Jun 2012 |
| Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting NCT01388920Theratechnologies | Phase 2 | Stopped early | 3 | Sep 2011 |
| Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® NCT01579695Theratechnologies | Observational | Stopped early | 391 | Feb 2013 |
1 further registry entry from a sponsor we could not verify is not listed.
Latest key papers
PubMed · newest first
- 2026
Meta-analysisDitta AM et al. · Journal of the International Association of Providers of AIDS CarePMID 42538058
- 2026
Meta-analysisBadran AS et al. · Obesity Research & Clinical PracticePMID 41545261
- 2025
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity
Human RCTPhase 2Ellis RJ et al. · The Journal of Infectious DiseasesPMID 39813152
- 2024
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors
Human RCTRusso SC et al. · AIDSPMID 38905488
- 2020
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
Human RCTFourman LT et al. · JCI InsightPMID 32701508
- 2019
Human RCTStanley TL et al. · The Lancet. HIVPMID 31611038
- 2019
Human RCTAdrian S et al. · The Journal of Frailty & AgingPMID 31237318
- 2017
Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation
Human RCTBraun LR et al. · Growth Hormone & IGF ResearchPMID 29031905